Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | FLT3 |
| Variant | V592A |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | FLT3 V592A lies within a region important for maintaining kinase activity in the Flt3 protein (UniProt.org). V592A results in constitutive phosphorylation of Flt3, activation of Stat5 signaling, upregulation of Bcl-x(L), and is transforming in cell culture (PMID: 16410449). |
| Associated Drug Resistance | |
| Category Variants Paths |
FLT3 mutant FLT3 act mut FLT3 V592A FLT3 mutant FLT3 exon14 FLT3 V592A |
| Transcript | NM_004119.3 |
| gDNA | chr13:g.28034144A>G |
| cDNA | c.1775T>C |
| Protein | p.V592A |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_004119.2 | chr13:g.28034144A>G | c.1775T>C | p.V592A | RefSeq | GRCh38/hg38 |
| NM_004119 | chr13:g.28034144A>G | c.1775T>C | p.V592A | RefSeq | GRCh38/hg38 |
| NM_004119.3 | chr13:g.28034144A>G | c.1775T>C | p.V592A | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 V592A | hematologic cancer | sensitive | Gilteritinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 V592A in culture (PMID: 40196870). | 40196870 |
| FLT3 V592A | hematologic cancer | sensitive | Quizartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 V592A in culture (PMID: 40196870). | 40196870 |
| FLT3 V592A | hematologic cancer | sensitive | Midostaurin | Preclinical - Cell culture | Actionable | In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 V592A in culture (PMID: 40196870). | 40196870 |